Note: The VIRUS as the smokescreen!
Sir Patrick Vallance FRS FMedSci FRCP is Government Chief Scientific Adviser (GCSA) and Head of the Government Science and Engineering (GSE) profession.
Patrick was President, R&D at GlaxoSmithKline (GSK) from 2012 until 2017. Prior to this, he was Senior Vice President, Medicines Discovery and Development. He joined the company in May 2006 as Head of Drug Discovery. He was a member of the GSK Board and the Corporate Executive Team. During his period as head of R&D over 14 new medicines were approved for use worldwide, for diseases ranging from cancer to asthma and HIV.
This blogger asserts that vaccines are not safe or effective. Their continued use in light of our better understanding of human health is due to medical indoctrination, profiteering and population management.
The legal immunity given to vaccine manufacturers is akin to the immunity given to the bankers and their affiliated services.
Very few would defend the banking industry and its affiliates engaged in frauds – mortgage, libor, forex, futures, gold, silver, interests rates, laundering or tax evasion, yet we note the flaccid response of the western prosecutors.
The single exception being Iceland.
It occured to me that the executives on the board of GSK, Pfizer, Sanofi, Merck, Roche might wish to display their confidence in their line of vaccine products.
So here is the challenge:
That each executive member of the board of every vaccine producing pharmaceutical company produce an affidavit stating:
– that every vaccine they produce is safe.
– that every vaccine they produce has been tested.
– that every vaccine they produce is effective.
– that they have NOT seen any adverse effects of their vaccine products.
– that they will accept full commercial liability for the claimed safety of their vaccine product.
Will Bill Gates, Zuckerberg, Soros, Rockfeller, Bloomberg and others put up the funds to support their vaccine pushing friends?
It is safe? Let us see that public declaration under oath from every member of the board.
They can no longer claim ignorance and are directly culpable in any internal frauds committed to hide, obfuscate the truth if their assertions under oath are indeed false.
GSK, Pfizer, Riche, Merck, Astrazeneca, we are waiting…Vaccine Oath/Affidavit Challange!
Note: The Polish government paid a high price for non-compliance. Have your noticed nation states fall quickly in line with W.H.O. decrees with a very few non-aligned exceptions.
Here’s the Company That’s the Closest to developing a Zika Vaccine
by Laura Lorenzetti January 28, 2016, 5:37 PM E
[Full article copied for archival purposes, is informational and non-commercial]
The Zika virus has spread rapidly across the Americas, arriving in Brazil last May and creeping into 22 other countries and territories around the region. The virus’ spread has been accompanied by a steep increase in babies born with abnormally small heads and in cases of Guillain-Barre syndrome, an uncommon nervous system disease. This has raised the alarm among public health officials around the world—and launched the quest for a vaccine that could stop its spread.
The U.S. and international governments are pushing forward with programs for Zika vaccines, and at least three pharmaceutical companies are either considering or actively pursing programs, including giants GlaxoSmithKlineGSK, and Sanofi SNY. But the company that appears to be the farthest along is a relatively small $500 million market cap biotech named Inovio Pharmacuetucals INO. Wall Street has shown interest in the company. Inovio’s stock was up about 8% today on news that it is entering clinical trials with its MERS vaccine, which could also hold promise for a future Zika vaccine.
Nonetheless, even Inovio is likely a ways off from developing a human Zika vaccine.
“It is important to understand that we will not have a widely available, safe, and effective Zika vaccine this year, and probably not even in the next few years,” Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), said in a press conference.
The advantage of Zika vaccine programs is that they can use similar mosquito-based diseases, part of a family called flaviviruses, like dengue, West Nile virus, and chikungunya as a “jumping off” point. While researchers are currently trying to learn more about the basics of the Zika virus and its effects on the human body given how new the disease is, they can already use past vaccine development platforms from other flaviviruses as a foundation since they spread in similar ways.
NIAID is already working on two approaches: a DNA-based vaccine, similar to a strategy used for West Nile virus, which has been found safe and effective in a phase one trial. It is also working on a more traditional killed virus-vaccine, similar to those already developed to prevent dengue.
Traditional killed-virus(?) vaccines, also called live-attenuated vaccines, are what most of us are used to. They are grown in eggs using live viruses, and then made inactive by a chemical process, and are the basis for the vast majority of vaccines we take as children and annually to prevent the flu. They are time intensive to develop, typically requiring between 10 and 15 years before they are approved, according to GlaxoSmithKline.
DNA-based vaccines, on the other hand, can reduce that development time by creating a synthetic DNA sequence in a lab that can trigger the human body to create the same antigens as from a killed virus. This cuts development time since it doesn’t need to grow a live virus, which can have unpredictable development pathways.
Inovio Pharmaceuticals has also been working on a DNA-based vaccine for Zika since December. In that time, Inovio has created a DNA strand that can potentially prevent the virus, using its knowledge from its dengue virus program. It is now testing the vaccine in mice and plans to move into testing primates “in the next few weeks,” said Inovio CEO J. Joseph Kim. Once its safety is confirmed, the vaccine will move into phase one testing in humans—as soon as the end of 2016.
“The beauty of this technological platform is that the vaccine is simply a DNA sequence developed in water,” said Kim. “It cuts through all the difficult handling and complex development times of traditional vaccine approaches.”
Inovio has taken this same approach with an Ebola vaccine, going from “bench to clinic”—researcher terms, meaning from initial creation to human testing—in just over 18 months. That program attracted the interest of the U.S. Defense Advanced Research Projects Agency (DARPA), which gave the company $45 million to support the program’s ongoing development. The biotech is also working on a DNA-based vaccine for MERS, which has gone from its creation in a lab to a phase one trial at Walter Reed Army Institute of Research in just over a year.
Still, while animal applications of these preventatives have been approved in animals, DNA-based vaccines are one of the latest medical advancements, and one has yet to be approved for use in humans in the U.S. Even though Inovio has attracted fans on Wall Street, it still has a lot to prove.
Note: Open declaration that the synthetic virologists can and will create viruses or virus fragments to pollute, contaminate your sovereign earthly vehicle for profit!
Don’t forget in the US they are indemnified against lawsuits. They are protected from any harm or damage that their synthetic DNA vaccines cause. A BIG MORAL HAZARD.
“Since 29 November, not a single new Ebola case has been reported in Guinea, Sierra Leone, or Liberia. If no new cases pop up, the world will be able to declare on 14 January that the 2-year Ebola epidemic has ended at last, after more than 28,600 cases and 11,300 deaths.
Victory would also mean the end of an unprecedented era in Ebola research. The tragedy offered a unique opportunity: Never before had the disease affected enough people to allow researchers to test Ebola drugs and vaccines in a real-world setting. As the number of cases exploded in mid-2014, they set in motion a vast research program that operated at breakneck speed.
But the harvest of that massive effort is thin.
The biggest success so far is a vaccine produced by Merck. A 31 July report in The Lancet documented remarkable effectiveness in a real-world trial in Guinea. But all other results have yet to appear in the scientific literature. And a careful examination of the data so far—supported by dozens of interviews with the leaders of the studies and other Ebola experts—makes it clear that almost every other trial seems destined to end in questionable results or outright failure. Findings from those that have ended are proving difficult to publish in top-tier journals.”
Note: Personally, “Ebola” was a sickening awakening to the massive global interconnected fraud that is pharma and the vaccine peddling national and supranational bodies.